Gsa Capital Partners LLP T Scan Therapeutics, Inc. Call Options Transaction History
Gsa Capital Partners LLP
- $1.11 Billion
- Q1 2025
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding TCRX
# of Institutions
92Shares Held
39.8MCall Options Held
0Put Options Held
0-
Lynx1 Capital Management LP San Juan, PR5.36MShares$8.25 Million2.73% of portfolio
-
Bvf Inc San Francisco, CA4.89MShares$7.53 Million0.3% of portfolio
-
Black Rock Inc. New York, NY4.46MShares$6.87 Million0.0% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA3.5MShares$5.39 Million0.01% of portfolio
-
Baker Bros. Advisors LP New York, NY2.78MShares$4.29 Million0.05% of portfolio
About TScan Therapeutics, Inc.
- Ticker TCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 18,929,800
- Market Cap $29.2M
- Description
- TScan Therapeutics, Inc., a preclinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell therapies for the treatment of patients with cancer. It is developing TSC-100 and TSC-101 for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell ...